Evolving Story of Clinical Trials in Hypertrophic Cardiomyopathy

Elliott, Perry

doi:10.1161/circheartfailure.117.004572

Cited by 6 publications

(2 citation statements)

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there have been significant advances in the understanding of the endothelium in HCM progression and pathogenesis, there are no clinical trials assessing endothelium-targeted therapies to date. Clinical trials for late sodium current inhibitors ranolazine and eleclazine have also not yielded any evidence of efficacy ( Elliott, 2018 ). The relative rarity of HCM adds to the difficulty of conducting suitably powered randomized controlled trials necessary for revealing small therapeutic effects in new candidate drugs.…”

Section: Humoral and Biomechanical Drivers Of Endothelial Dysfunctionmentioning

confidence: 99%

Endothelial cell dysfunction in cardiac disease: driver or consequence?

Allbritton-King,

García-Cardeña

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The vascular endothelium is a multifunctional cellular system which directly influences blood components and cells within the vessel wall in a given tissue. Importantly, this cellular interface undergoes critical phenotypic changes in response to various biochemical and hemodynamic stimuli, driving several developmental and pathophysiological processes. Multiple studies have indicated a central role of the endothelium in the initiation, progression, and clinical outcomes of cardiac disease. In this review we synthesize the current understanding of endothelial function and dysfunction as mediators of the cardiomyocyte phenotype in the setting of distinct cardiac pathologies; outline existing in vivo and in vitro models where key features of endothelial cell dysfunction can be recapitulated; and discuss future directions for development of endothelium-targeted therapeutics for cardiac diseases with limited existing treatment options.

show abstract

Section: Humoral and Biomechanical Drivers Of Endothelial Dysfunctionmentioning

confidence: 99%

Endothelial cell dysfunction in cardiac disease: driver or consequence?

Allbritton-King,

García-Cardeña

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…As regards the nonobstructive HCM, in 2018 Olivotto et al, showed that ranolazine although had no great effect on exercise capacity, plasma proBNP levels, diastolic heart failure, or quality of life, was safe and effective in reducing the amount of ventricular extrasystoles, in a cohort of 80 patients [20]. These results could be a consequence of the complexity in the definition of HCM that includes several characteristics that can somehow hinder the path of a randomized trial [21]. Concerning the heart failure, this study gave an explication to the results of a previous one by Murray et al who investigated the effect of ranolazine on ejection fraction (EF) in patients with systolic or diastolic disfunction.…”

Section: Coronary Artery and Myocardium Diseasesmentioning

confidence: 99%

Through the heart and beyond: a review on ranolazine

Uran¹

2021

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable angina. It acts by selectively inhibiting the late sodium inward current. Moreover, ranolazine has other metabolic features which makes it effective in other diseases as well as coronary artery ones. In this paper I make an updated review of all possible therapeutic roles of ranolazine: through cardiology and beyond.

show abstract